CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 76% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
21.93
1.53%
  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading Conditions
Spread 0.07
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026151 %
Charges from full value of position ($-4.97)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026151%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003929 %
Charges from full value of position ($0.75)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003929%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Veracyte Inc ESG Risk Ratings

High Medium Low Negligible

‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 22.27
Open* 22.07
1-Year Change* 33.11%
Day's Range* 21.67 - 22.12
52 wk Range 14.92-32.40
Average Volume (10 days) 452.48K
Average Volume (3 months) 12.42M
Market Cap 1.84B
P/E Ratio -100.00K
Shares Outstanding 72.75M
Revenue 328.63M
EPS -0.40
Dividend (Yield %) N/A
Beta 1.32
Next Earnings Date Oct 31, 2023

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Sep 29, 2023 22.27 -0.71 -3.09% 22.98 23.37 22.14
Sep 28, 2023 22.85 -0.02 -0.09% 22.87 23.41 22.33
Sep 27, 2023 22.83 0.65 2.93% 22.18 23.06 22.18
Sep 26, 2023 22.55 0.33 1.49% 22.22 23.04 22.22
Sep 25, 2023 22.44 0.22 0.99% 22.22 22.73 22.02
Sep 22, 2023 22.45 -0.20 -0.88% 22.65 22.84 22.12
Sep 21, 2023 22.55 -0.42 -1.83% 22.97 22.97 22.37
Sep 20, 2023 23.27 -0.88 -3.64% 24.15 24.41 23.27
Sep 19, 2023 24.08 -0.04 -0.17% 24.12 24.44 23.57
Sep 18, 2023 24.28 -0.56 -2.25% 24.84 25.06 24.27
Sep 15, 2023 25.00 -0.19 -0.75% 25.19 25.24 24.69
Sep 14, 2023 25.16 -0.20 -0.79% 25.36 25.53 24.85
Sep 13, 2023 25.32 0.08 0.32% 25.24 25.96 25.24
Sep 12, 2023 25.23 0.16 0.64% 25.07 25.63 24.97
Sep 11, 2023 25.25 0.56 2.27% 24.69 25.40 24.59
Sep 8, 2023 24.64 -0.56 -2.22% 25.20 25.35 24.58
Sep 7, 2023 25.28 -0.05 -0.20% 25.33 25.65 25.17
Sep 6, 2023 25.98 0.42 1.64% 25.56 26.41 25.56
Sep 5, 2023 26.15 -0.09 -0.34% 26.24 26.62 26.00
Sep 1, 2023 26.65 -0.04 -0.15% 26.69 27.16 26.22

Veracyte Inc Events

Time (UTC) Country Event
Tuesday, October 31, 2023

Time (UTC)

10:59

Country

US

Event

Q3 2023 Veracyte Inc Earnings Release
Q3 2023 Veracyte Inc Earnings Release

Forecast

-

Previous

-
Tuesday, February 20, 2024

Time (UTC)

10:59

Country

US

Event

Q4 2023 Veracyte Inc Earnings Release
Q4 2023 Veracyte Inc Earnings Release

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 296.536 219.514 117.483 120.368 92.008
Revenue 296.536 219.514 117.483 120.368 92.008
Cost of Revenue, Total 101.582 74.4 41.455 36.523 33.078
Gross Profit 194.954 145.114 76.028 83.845 58.93
Total Operating Expense 337.617 301.417 152.872 135.495 114.241
Selling/General/Admin. Expenses, Total 168.533 134.843 87.585 81.312 63.623
Research & Development 40.079 29.531 16.962 14.564 14.42
Depreciation / Amortization 24.123 18.143 6.87 3.096 3.12
Operating Income -41.081 -81.903 -35.389 -15.127 -22.233
Interest Income (Expense), Net Non-Operating 1.971 -1.187 -0.229 -0.677 -1.963
Other, Net 2.683 1.441 0.709 3.205 1.197
Net Income Before Taxes -36.427 -81.649 -34.909 -12.599 -22.999
Net Income After Taxes -36.56 -75.563 -34.909 -12.599 -22.999
Net Income Before Extra. Items -36.56 -75.563 -34.909 -12.599 -22.999
Net Income -36.56 -75.563 -34.909 -12.599 -22.999
Income Available to Common Excl. Extra. Items -36.56 -75.563 -34.909 -12.599 -22.999
Income Available to Common Incl. Extra. Items -36.56 -75.563 -34.909 -12.599 -22.999
Diluted Net Income -36.56 -75.563 -34.909 -12.599 -22.999
Diluted Weighted Average Shares 71.5492 67.8903 53.2392 46.1382 37.0202
Diluted EPS Excluding Extraordinary Items -0.51098 -1.11302 -0.6557 -0.27307 -0.62125
Diluted Normalized EPS -0.481 -0.90142 -0.6557 -0.27307 -0.62125
Total Extraordinary Items
Dividends per Share - Common Stock Primary Issue
Unusual Expense (Income) 3.3 22.1
Other Operating Expenses, Total 22.4
Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
Total revenue 90.322 82.422 80.297 75.592 72.864
Revenue 90.322 82.422 80.297 75.592 72.864
Cost of Revenue, Total 29.688 26.229 26.831 26.008 25.03
Gross Profit 60.634 56.193 53.466 49.584 47.834
Total Operating Expense 98.373 92.92 85.717 85.272 83.597
Selling/General/Admin. Expenses, Total 50.051 46.481 41.688 42.731 39.964
Research & Development 12.268 12.606 11.123 10.647 9.256
Depreciation / Amortization 6.366 6.204 6.075 5.886 6.047
Unusual Expense (Income) 1.4 0 3.3
Other Operating Expenses, Total
Operating Income -8.051 -10.498 -5.42 -9.68 -10.733
Interest Income (Expense), Net Non-Operating 1.173 1.411 2.013 -0.085 -0.223
Other, Net -1.399 0.996 -0.034 0.89 1.309
Net Income Before Taxes -8.277 -8.091 -3.441 -8.875 -9.647
Net Income After Taxes -8.402 -8.091 -3.844 -8.723 -9.532
Net Income Before Extra. Items -8.402 -8.091 -3.844 -8.723 -9.532
Net Income -8.402 -8.091 -3.844 -8.723 -9.532
Income Available to Common Excl. Extra. Items -8.402 -8.091 -3.844 -8.723 -9.532
Income Available to Common Incl. Extra. Items -8.402 -8.091 -3.844 -8.723 -9.532
Diluted Net Income -8.402 -8.091 -3.844 -8.723 -9.532
Diluted Weighted Average Shares 72.4787 72.1755 71.8288 71.6567 71.477
Diluted EPS Excluding Extraordinary Items -0.11592 -0.1121 -0.05352 -0.12173 -0.13336
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -0.11592 -0.0927 -0.05352 -0.12173 -0.10335
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 248.636 243.102 375.679 187.687 96.952
Cash and Short Term Investments 178.852 173.197 349.364 159.317 77.995
Cash & Equivalents 154.247 173.197 349.364 159.317 77.995
Total Receivables, Net 44.021 41.461 18.461 19.329 13.168
Accounts Receivable - Trade, Net 44.021 41.461 18.461 19.329 13.168
Total Inventory 14.294 11.225 4.657 6.806 3.402
Prepaid Expenses 11.469 17.219 3.197 2.235 2.387
Other Current Assets, Total
Total Assets 1156.42 1187.82 457.163 275.212 120.638
Property/Plant/Equipment, Total - Net 30.862 31.141 16.833 17.741 8.94
Property/Plant/Equipment, Total - Gross 56.844 52.622 33.23 31.821 20.946
Accumulated Depreciation, Total -25.982 -21.481 -16.397 -14.08 -12.006
Goodwill, Net 695.891 707.904 2.725 2.725 1.057
Intangibles, Net 174.866 202.731 59.924 65.019 12
Other Long Term Assets, Total 6.167 2.947 2.002 2.04 1.689
Total Current Liabilities 62.614 64.151 16.781 17.469 13.059
Accounts Payable 11.911 12.36 3.116 2.328 2.516
Accrued Expenses 41.844 43.105 13.294 15.141 9.186
Notes Payable/Short Term Debt 0 0 0 0 0
Other Current Liabilities, Total 8.859 7.559 0.371
Total Liabilities 81.222 91.311 35.931 35.757 40.883
Total Long Term Debt 0.4 0.6 0.81 0.694 23.925
Long Term Debt 0 0.81 0.694 23.925
Capital Lease Obligations 0.4 0.6 0
Other Liabilities, Total 13.677 20.968 18.34 17.594 3.899
Total Equity 1075.2 1096.51 421.232 239.455 79.755
Preferred Stock - Non Redeemable, Net 0 0 0 0
Common Stock 0.072 0.071 0.058 0.05 0.041
Additional Paid-In Capital 1500.19 1468.68 702.768 486.09 313.8
Retained Earnings (Accumulated Deficit) -393.717 -357.157 -281.594 -246.685 -234.086
Total Liabilities & Shareholders’ Equity 1156.42 1187.82 457.163 275.212 120.638
Total Common Shares Outstanding 71.9594 71.1231 58.2005 49.6253 40.8632
Current Port. of LT Debt/Capital Leases 0 1.127 0 1.357
Deferred Income Tax 4.531 5.592
Other Equity, Total -31.346 -15.083
Short Term Investments 24.605
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Total Current Assets 251.503 248.636 238.516 235.045 238.483
Cash and Short Term Investments 177.89 178.852 170.112 163.998 163.615
Cash & Equivalents 177.89 154.247 170.112 153.447 163.615
Total Receivables, Net 45.489 44.021 40.068 40.448 42.481
Accounts Receivable - Trade, Net 45.489 44.021 40.068 40.448 42.481
Total Inventory 13.306 14.294 13.798 14.6 12.372
Prepaid Expenses 14.818 11.469 14.538 15.999 20.015
Total Assets 1157.12 1156.42 1125.96 1144.2 1173.59
Property/Plant/Equipment, Total - Net 29.38 30.862 31.122 32.004 31.962
Goodwill, Net 699.718 695.891 676.885 690.04 704.368
Intangibles, Net 170.226 174.866 176.542 184.367 196.228
Other Long Term Assets, Total 6.292 6.167 2.892 2.742 2.548
Total Current Liabilities 55.993 62.614 58.352 59.345 62.543
Accounts Payable 15.655 11.911 11.114 10.328 11.273
Accrued Expenses 34.717 41.844 36.095 37.495 42.392
Notes Payable/Short Term Debt 0 0 0 0 0
Other Current Liabilities, Total 5.621 8.859 9.956 10.389 7.799
Total Liabilities 75.86 81.222 77.78 80.047 88.399
Total Long Term Debt 0.2 0.4 0.5 0.6 0.6
Long Term Debt
Deferred Income Tax 4.594 4.531 4.342 4.605 4.983
Other Liabilities, Total 15.073 13.677 14.586 15.497 20.273
Total Equity 1081.26 1075.2 1048.18 1064.15 1085.19
Common Stock 0.072 0.072 0.072 0.072 0.071
Additional Paid-In Capital 1509.86 1500.19 1492.04 1483.28 1477.42
Retained Earnings (Accumulated Deficit) -401.808 -393.717 -389.873 -381.15 -371.618
Total Liabilities & Shareholders’ Equity 1157.12 1156.42 1125.96 1144.2 1173.59
Total Common Shares Outstanding 72.3831 71.9594 71.7415 71.5585 71.4329
Capital Lease Obligations 0.2 0.4 0.5 0.6 0.6
Preferred Stock - Non Redeemable, Net 0 0 0 0 0
Other Equity, Total -26.866 -31.346 -54.066 -38.05 -20.681
Current Port. of LT Debt/Capital Leases 0 1.187 1.133 1.079
Short Term Investments 0 24.605 0 10.551
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line -36.56 -75.563 -34.909 -12.599 -22.999
Cash From Operating Activities 7.535 -31.621 -9.711 -3.232 -13.521
Cash From Operating Activities 25.928 19.593 7.944 4.117 3.92
Non-Cash Items 34.415 26.388 17.735 10.096 6.209
Cash Taxes Paid 0.57 0.112 0.112 0.035 0.079
Cash Interest Paid 0.009 0.009 0.013 0.332 1.547
Changes in Working Capital -16.381 4.219 -0.481 -4.846 -0.651
Cash From Investing Activities -29.387 -739.206 -3.837 -42.733 -1.874
Capital Expenditures -8.549 -5.376 -2.837 -2.756 -1.874
Other Investing Cash Flow Items, Total -20.838 -733.83 -1 -39.977 0
Cash From Financing Activities 3.494 596.32 203.595 127.287 59.499
Financing Cash Flow Items -3.167 -9.029 -3.845 0 0.403
Issuance (Retirement) of Stock, Net 7.942 605.349 207.54 152.495 59.388
Issuance (Retirement) of Debt, Net -1.281 0 -0.1 -25.208 -0.292
Net Change in Cash -18.95 -176.021 190.047 81.322 44.104
Deferred Taxes 0.133 -6.258
Foreign Exchange Effects -0.592 -1.514
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line -8.091 -36.56 -32.716 -23.993 -14.461
Cash From Operating Activities -2.172 7.535 -2.209 -9.235 -8.872
Cash From Operating Activities 6.67 25.928 19.372 13.048 6.556
Deferred Taxes 0 0.133 -0.27 -0.118 -0.003
Non-Cash Items 9.71 34.415 27.388 18.315 7.447
Cash Interest Paid 0.009 0 0 0
Changes in Working Capital -10.461 -16.381 -15.983 -16.487 -8.411
Cash From Investing Activities 24.08 -29.387 -2.953 -11.76 -2.453
Capital Expenditures -0.993 -8.549 -6.677 -4.963 -2.453
Other Investing Cash Flow Items, Total 25.073 -20.838 3.724 -6.797 0
Cash From Financing Activities 1.685 3.494 3.401 1.915 1.99
Financing Cash Flow Items -2.277 -3.167 -2.639 -1.865 -1.447
Issuance (Retirement) of Stock, Net 3.962 7.942 6.134 3.877 3.537
Issuance (Retirement) of Debt, Net 0 -1.281 -0.094 -0.097 -0.1
Net Change in Cash 23.643 -18.95 -3.085 -19.75 -9.582
Foreign Exchange Effects 0.05 -0.592 -1.324 -0.67 -0.247
Cash Taxes Paid 0.57 -0.43 0.064

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Veracyte Inc Company profile

About Veracyte Inc

Veracyte, Inc. is a genomic diagnostics company. The Company offers customized biomarker testing and analytical services. It offers a complete range of in vitro diagnostic (IVD) and companion diagnostic development services to biopharmaceutical companies and diagnostic companies. It offers tests across various diseases, which include Afirma Genomic Sequencing Classifier for thyroid cancer; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer; Prosigna Breast Cancer Assay for breast cancer; Genomic Sequencing Classifier and Percepta Nasal Swab Test for lung cancer; Envisia Genomic Classifier test for interstitial lung diseases; Decipher Bladder Genomic Classifier test for bladder cancer and Immunoscore Colon Cancer Test for colon cancer. It also offers Immunogram, a spatial molecular analysis and bioinformatics tool that integrates genomic, transcriptomic and proteomic data to help researchers understand the intricacies of the tumor immune microenvironment.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Veracyte Inc revenues increased 87% to $219.5M. Net loss increased from $34.9M to $75.6M. Revenues reflect United States segment increase of 83% to $201M, International segment increase from $7.9M to $18.5M. Higher net loss reflects Selling and marketing - Balancing value increase of 54% to $75.4M (expense), General & Administrative Expenses increase of 47% to $42.2M (expense).

Equity composition

Common Stock, $0.001 Par, 10/13, 125M auth., 20,989,890 issd., Insiders Own 76.17%

Industry: Bio Diagnostics & Testing

6000 Shoreline Court, Suite 300
SOUTH SAN FRANCISCO
CALIFORNIA 94080
US

Income Statement

  • Annual
  • Quarterly

News

How to Trade The Triple Top

Welcome to Part 5 of our 7-part Power Patterns series. In this series, we'll be equipping you with the skills to trade some of the most indicative price patterns which occur on any timeframe in every market.

14:13, 27 September 2023
USA flag on the background of stock charts. Financial system in USA

Q4 lookahead: US indices starting to show signs of trouble?

US indices start to draw attention as traders focus on the outlook for Q4.

07:20, 27 September 2023

USD/JPY Climbs Towards Key Highs

USDJPY’s powerful long-term uptrend has been reignited after last week’s sharply contrasting policy statements from the Federal Reserve and Bank of Japan.

11:32, 26 September 2023

EUR/USD tests key support

EUR/USD is currently testing a key support level after the Federal Reserve indicated a potential extension of higher interest rates.

14:32, 21 September 2023
Bank of England building

BoE leaves rates unchanged, GBP drops further as investors look for more clarity

The Bank of England has left rates unchanged at 5.25% with a 5-4 vote split after CPI dropped more than expected in August

11:45, 21 September 2023
British banknotes and coins photographed directly above. The coins are in a stack, placed on top of the banknotes.

GBP softer after CPI surprise, JPY focused on any further hints from Ueda

GBP drops after a softer CPI reading scares investors about the BoE intentions. JPY on the lookout for further policy tweaks from Governor Ueda.

12:42, 20 September 2023

How to Trade The Break & Retest

In this week's instalment, we delve into the Break & Retest pattern—a strategic approach to navigating breakout trades. If you've wrestled with the frustration of false breakouts, incorporating this pattern into your trading toolkit may help you overcome this challenge and put you on the path to becoming a more confident and consistent trader.

11:59, 20 September 2023

People also watch

Gold

1,828.09 Price
-1.120% 1D Chg, %
Long position overnight fee -0.0195%
Short position overnight fee 0.0113%
Overnight fee time 21:00 (UTC)
Spread 0.30

Oil - Crude

87.89 Price
-2.380% 1D Chg, %
Long position overnight fee 0.0589%
Short position overnight fee -0.0808%
Overnight fee time 21:00 (UTC)
Spread 0.030

US100

14,841.80 Price
+0.660% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0039%
Overnight fee time 21:00 (UTC)
Spread 7.0

BTC/USD

27,840.25 Price
+2.750% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 85.00

Still looking for a broker you can trust?

Join the 555.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading